Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-international-ag-patient-reported-outcomes-tool-revealed-significant-improvement-symptom-frequency-and-quality-life-domains-entrestoOverall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]…
- https://www.novartis.com/news/media-releases/sandoz-receives-european-commission-approval-zessly-infliximab-gastroenterological-rheumatological-and-dermatological-diseasesEuropean Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable…
- https://www.novartis.com/news/media-releases/novartis-and-amgen-announce-fda-approval-aimovigtm-erenumab-novel-treatment-developed-specifically-migraine-preventionMigraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
- https://www.novartis.com/news/media-releases/novartis-data-asco-and-eha-reinforce-companys-commitment-reimagining-cancerResults from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will…
- https://www.novartis.com/news/media-releases/novartis-kundigt-veranderungen-der-geschaftsleitungFelix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt…
- https://www.novartis.com/news/media-releases/meet-novartis-management-investor-event-novartis-highlights-strategy-focus-company-and-drive-sustainable-growthFull pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,…
- https://www.novartis.com/news/media-releases/novartis-announces-changes-executive-committeeFelix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services…
- https://www.novartis.com/news/media-releases/novartis-successfully-completes-acquisition-avexis-incThe digital press release with multimedia content can be accessed here: Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of…
- https://www.novartis.com/news/media-releases/novartis-arrow-trial-assess-mechanistic-superiority-direct-il-17a-inhibition-cosentyx-over-il-23-inhibition-tremfyaARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 inhibition (Tremfya®*) in clearing of Stelara®*-resistant psoriatic plaques[1] This is the…
- https://www.novartis.com/news/media-releases/novartis-completes-tender-offer-all-outstanding-shares-avexis-incBasel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Novartis AM…
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 263
- › Next page